Brief: Veru Reaches Agreement With FDA On New Phase 3 Clinical Trial For Sabizabulin

Veru

26/09/2023 13:36

Sept 26 (Reuters) - Veru Inc  VERU.O :
    * VERU REACHES AGREEMENT WITH FDA ON NEW PHASE 3 CLINICAL
TRIAL
FOR SABIZABULIN FOR BROADER INDICATION: HOSPITALIZED ADULT
PATIENTS WITH ANY TYPE OF VIRAL ACUTE RESPIRATORY DISTRESS
SYNDROME (ARDS)
    * VERU INC - COMPANY PLANS TO CONDUCT "ALL COMERS" VIRAL
ARDS
PHASE 3 STUDY INSTEAD OF SECOND CONFIRMATORY PHASE 3 COVID-19
STUDY
    * VERU INC - ENROLLMENT COULD BEGIN AS EARLY AS CALENDAR Q4
2023

Source text for Eikon:  ID:nGNX3Sjphq 
Further company coverage:  VERU.O 

 ((Reuters.Briefs@thomsonreuters.com;))